Literature DB >> 26285657

Targeted Disruption of the β2-Microglobulin Gene Minimizes the Immunogenicity of Human Embryonic Stem Cells.

Dachun Wang1, Yuan Quan2, Qing Yan2, John E Morales2, Rick A Wetsel1.   

Abstract

UNLABELLED: Human embryonic stem cells (hESCs) are a promising source of cells for tissue regeneration, yet histoincompatibility remains a major challenge to their clinical application. Because the human leukocyte antigen class I (HLA-I) molecules are the primary mediators of immune rejection, we hypothesized that cells derived from a hESC line lacking HLA-I expression could be transplanted without evoking a robust immune response from allogeneic recipients. In the present study, we used the replacement targeting strategy to delete exons 2 and 3 of β2-microglobulin on both gene alleles in hESCs. Because β2-microglobulin serves as the HLA-I light chain, disruption of the β2-microglobulin gene led to complete HLA-I deficiency on the cell surface of hESCs and their derivatives. Therefore, these cells were resistant to CD8+ T-cell-mediated destruction. Although interferon-γ (IFN-γ) treatment significantly induced β2-microglobulin expression, promoting CD8+ T cell-mediated killing of control hESCs and their derivatives, CD8+ T-cell-mediated cytotoxicity was barely observed with β2-microglobulin-null hESCs and their derivatives treated with IFN-γ. This genetic manipulation to disrupt HLA-I expression did not affect the self-renewal capacity, genomic stability, or pluripotency of hESCs. Despite being relatively sensitive to natural killer (NK) cell-mediated killing due to the lack of HLA-I expression, when transplanted into NK cell-depleted immunocompetent mice, β2-microglobulin-null hESCs developed into tumors resembling those derived from control hESCs in severe combined immunodeficiency mice. These results demonstrate that β2-microglobulin-null hESCs significantly reduce immunogenicity to CD8+ T cells and might provide a renewable source of cells for tissue regeneration without the need for HLA matching in the future. SIGNIFICANCE: This study reports the generation of a novel β2-microglobulin (B2M)-/- human embryonic stem cell (hESC) line. Differentiated mature cells from this line do not express cell surface human leukocyte antigen molecules even after interferon-γ stimulation and are resistant to alloreactive CD8+ T cells. Moreover, this B2M-/- hESC line contains no off-target integration or cleavage events, is devoid of stable B2M mRNA, exhibits a normal karyotype, and retains its self-renewal capacity, genomic stability, and pluripotency. Although B2M-/- hESC-derived cells are more susceptible to natural killer (NK) cells, murine transplantation studies have indicated that they are, overall, much less immunogenic than normal hESCs. Thus, these data show for the first time that, in vivo, the advantages provided by B2M-/- hESC-derived cells in avoiding CD8+ T-cell killing appear significantly greater than any disadvantage caused by increased susceptibility to NK cells. ©AlphaMed Press.

Entities:  

Keywords:  Differentiation and characterization; Human leukocyte antigen class I; Immunogenicity of human embryonic stem cells; β2-Microglobulin gene targeting strategy

Mesh:

Substances:

Year:  2015        PMID: 26285657      PMCID: PMC4572902          DOI: 10.5966/sctm.2015-0049

Source DB:  PubMed          Journal:  Stem Cells Transl Med        ISSN: 2157-6564            Impact factor:   6.940


  59 in total

1.  TALENoffer: genome-wide TALEN off-target prediction.

Authors:  Jan Grau; Jens Boch; Stefan Posch
Journal:  Bioinformatics       Date:  2013-08-30       Impact factor: 6.937

2.  A site-specific genetic modification for induction of pluripotency and subsequent isolation of derived lung alveolar epithelial type II cells.

Authors:  Qing Yan; Yuan Quan; Huanhuan Sun; Xinmiao Peng; Zhengyun Zou; Joseph L Alcorn; Rick A Wetsel; Dachun Wang
Journal:  Stem Cells       Date:  2014-02       Impact factor: 6.277

3.  Immunoevasive pericytes from human pluripotent stem cells preferentially modulate induction of allogeneic regulatory T cells.

Authors:  Hagit Domev; Irina Milkov; Joseph Itskovitz-Eldor; Ayelet Dar
Journal:  Stem Cells Transl Med       Date:  2014-09-09       Impact factor: 6.940

4.  Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation.

Authors:  Veronika Groh; Jennifer Wu; Cassian Yee; Thomas Spies
Journal:  Nature       Date:  2002-10-17       Impact factor: 49.962

5.  Human embryonic stem cells derived by somatic cell nuclear transfer.

Authors:  Masahito Tachibana; Paula Amato; Michelle Sparman; Nuria Marti Gutierrez; Rebecca Tippner-Hedges; Hong Ma; Eunju Kang; Alimujiang Fulati; Hyo-Sang Lee; Hathaitip Sritanaudomchai; Keith Masterson; Janine Larson; Deborah Eaton; Karen Sadler-Fredd; David Battaglia; David Lee; Diana Wu; Jeffrey Jensen; Phillip Patton; Sumita Gokhale; Richard L Stouffer; Don Wolf; Shoukhrat Mitalipov
Journal:  Cell       Date:  2013-05-15       Impact factor: 41.582

6.  Generating hypoimmunogenic human embryonic stem cells by the disruption of beta 2-microglobulin.

Authors:  Pengfei Lu; Jijun Chen; Lixiazi He; Jiangtao Ren; Haide Chen; Lingjun Rao; Qinggang Zhuang; Hui Li; Lei Li; Lei Bao; Ji He; Wei Zhang; Faming Zhu; Chun Cui; Lei Xiao
Journal:  Stem Cell Rev Rep       Date:  2013-12       Impact factor: 5.739

Review 7.  Immunogenicity of in vitro maintained and matured populations: potential barriers to engraftment of human pluripotent stem cell derivatives.

Authors:  Chad Tang; Irving L Weissman; Micha Drukker
Journal:  Methods Mol Biol       Date:  2013

8.  Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells.

Authors:  Ryoko Araki; Masahiro Uda; Yuko Hoki; Misato Sunayama; Miki Nakamura; Shunsuke Ando; Mayumi Sugiura; Hisashi Ideno; Akemi Shimada; Akira Nifuji; Masumi Abe
Journal:  Nature       Date:  2013-01-09       Impact factor: 49.962

9.  Abnormalities in human pluripotent cells due to reprogramming mechanisms.

Authors:  Hong Ma; Robert Morey; Ryan C O'Neil; Yupeng He; Brittany Daughtry; Matthew D Schultz; Manoj Hariharan; Joseph R Nery; Rosa Castanon; Karen Sabatini; Rathi D Thiagarajan; Masahito Tachibana; Eunju Kang; Rebecca Tippner-Hedges; Riffat Ahmed; Nuria Marti Gutierrez; Crystal Van Dyken; Alim Polat; Atsushi Sugawara; Michelle Sparman; Sumita Gokhale; Paula Amato; Don P Wolf; Joseph R Ecker; Louise C Laurent; Shoukhrat Mitalipov
Journal:  Nature       Date:  2014-07-02       Impact factor: 49.962

10.  Broad specificity profiling of TALENs results in engineered nucleases with improved DNA-cleavage specificity.

Authors:  John P Guilinger; Vikram Pattanayak; Deepak Reyon; Shengdar Q Tsai; Jeffry D Sander; J Keith Joung; David R Liu
Journal:  Nat Methods       Date:  2014-02-16       Impact factor: 28.547

View more
  52 in total

1.  Generation of hypoimmunogenic human pluripotent stem cells.

Authors:  Xiao Han; Mengning Wang; Songwei Duan; Paul J Franco; Jennifer Hyoje-Ryu Kenty; Preston Hedrick; Yulei Xia; Alana Allen; Leonardo M R Ferreira; Jack L Strominger; Douglas A Melton; Torsten B Meissner; Chad A Cowan
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-30       Impact factor: 11.205

2.  Pluripotent stem cells that evade the immune radar.

Authors:  Steven C Kim; Andrew B Adams
Journal:  Nat Biotechnol       Date:  2017-08-08       Impact factor: 54.908

Review 3.  Immunological Issues After Stem Cell-Based β Cell Replacement.

Authors:  Valeria Sordi; Silvia Pellegrini; Lorenzo Piemonti
Journal:  Curr Diab Rep       Date:  2017-09       Impact factor: 4.810

Review 4.  Cell Therapy for Type 1 Diabetes: Current and Future Strategies.

Authors:  Yasaman Aghazadeh; Maria Cristina Nostro
Journal:  Curr Diab Rep       Date:  2017-06       Impact factor: 4.810

Review 5.  Engineering universal cells that evade immune detection.

Authors:  Robert Lanza; David W Russell; Andras Nagy
Journal:  Nat Rev Immunol       Date:  2019-08-15       Impact factor: 53.106

Review 6.  β Cell replacement: improving on the design.

Authors:  Roberto Castro-Gutierrez; Aaron W Michels; Holger A Russ
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2018-08       Impact factor: 3.243

7.  Elevated cerebrospinal fluid levels of beta-2-microglobulin in patients with Guillain-Barré syndrome and their correlations with clinical features.

Authors:  Ming-Qi Liu; Jing Wang; Chen-Na Huang; Yuan Qi; Lin-Jie Zhang; Ming Yi; Sheng-Hui Chang; Li-Sha Sun; Li Yang
Journal:  Neurol Sci       Date:  2021-02-17       Impact factor: 3.307

8.  CRISPR/Cas9 Ribonucleoprotein Complex-Mediated Efficient B2M Knockout in Human Induced Pluripotent Stem Cells (iPSCs).

Authors:  Nontaphat Thongsin; Methichit Wattanapanitch
Journal:  Methods Mol Biol       Date:  2022

Review 9.  Expression and function of immune ligand-receptor pairs in NK cells and cancer stem cells: therapeutic implications.

Authors:  Ioannis A Voutsadakis
Journal:  Cell Oncol (Dordr)       Date:  2018-02-22       Impact factor: 6.730

10.  Protecting Stem Cell Derived Pancreatic Beta-Like Cells From Diabetogenic T Cell Recognition.

Authors:  Roberto Castro-Gutierrez; Aimon Alkanani; Clayton E Mathews; Aaron Michels; Holger A Russ
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-09       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.